TherapeuticsMD Inc. priced its underwritten public offering of 26 million common shares at $2.75 per share.

The Boca Raton, Fla.-based company also granted a 30-day option to underwriters to buy up to an additional 3.9 million common shares at the same price.

The company expects $71.5 million in gross proceeds from the offering, assuming no exercise of the underwriters' option. TherapeuticsMD plans to use the net proceeds to commercialize its U.S. Food and Drug Administration-approved products Imvexxy, Bijuva and Annovera.

Imvexxy is used to treat severe dyspareunia — vaginal pain associated with sexual activity — a symptom of vulvar and vaginal atrophy due to menopause. Bijuva is approved for treating moderate to severe vasomotor symptoms, or hot flashes and night sweats, of menopause in women with a uterus. Annovera is a reusable combination hormonal contraceptive ring intended to prevent pregnancy.

J.P. Morgan is acting as sole book-running manager for the offering, while Stifel is acting as lead manager.